This is one of the largest sources of frustration currently among health care companies and investors.
Author: Global Cancer Consortium
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
The OneMedResearch January/February 2012 Issue discusses the developments of several small companies with intriguing technology in an emerging market. The report contains full financial updates of those companies designated as research clients as well as profiles of companies OneMedPlace has kept an eye on. This issue is particularly interesting as it comes in the wake of the OneMedForum conference in San Francisco, which brought these and dozens of other featured companies together with hundreds of high net worth investors, consultants, financiers and key opinion leaders. Over 90 companies presented at the conference, a unique educational and networking environment which included panel…
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
To date, most CTC capture and detection technologies have not been able to recognize the cytokeratin negative (CK‐) CTCs. Biocept’s Cell Enrichment and Extraction (CEETM) platform allows for the capture of these CK- cells as well as CK+ CTC phenotypes